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Abstract
Prostate cancer is the most commonly diagnosed malignancy among men in industrialized 
countries, accounting for the second leading cause of cancer-related deaths. While we now know 
that the androgen receptor (AR) is important for progression to the deadly advanced stages of the 
disease, it is poorly understood what AR-regulated processes drive this pathology. Here, we 
demonstrate that AR regulates prostate cancer cell growth via the metabolic sensor 5′-AMP-
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activated protein kinase (AMPK), a kinase that classically regulates cellular energy homeostasis. 
In patients, activation of AMPK correlated with prostate cancer progression. Using a combination 
of radiolabeled assays and emerging metabolomic approaches, we also show that prostate cancer 
cells respond to androgen treatment by increasing not only rates of glycolysis, as is commonly 
seen in many cancers, but also glucose and fatty acid oxidation. Importantly, this effect was 
dependent on androgen-mediated AMPK activity. Our results further indicate that the AMPK-
mediated metabolic changes increased intracellular ATP levels and peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α)-mediated mitochondrial biogenesis, 
affording distinct growth advantages to the prostate cancer cells. Correspondingly, we used outlier 
analysis to determine that PGC-1α is overexpressed in a subpopulation of clinical cancer samples. 
This was in contrast to what was observed in immortalized benign human prostate cells and a 
testosterone-induced rat model of benign prostatic hyperplasia. Taken together, our findings 
converge to demonstrate that androgens can co-opt the AMPK-PGC-1α signaling cascade, a 
known homeostatic mechanism, to increase prostate cancer cell growth. The current study points 
to the potential utility of developing metabolic-targeted therapies directed towards the AMPK-
PGC-1α signaling axis for the treatment of prostate cancer.
Keywords
androgen receptor; prostate cancer; AMP-activated protein kinase; peroxisome proliferator-
activated receptor γ coactivator 1α; metabolism
Introduction
Since the 1920's, it has been known that cancer cells possess the unique ability to alter their 
metabolism and, as such, are distinguishable from benign cells.1 However, it was only in the 
past decade that the reprogramming of energy metabolism has been acknowledged as one of 
the true emerging hallmarks of cancer.2 Interestingly, while the majority of metabolic cancer 
research focuses on the role of glycolysis, it has recently become apparent that the 
tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) also play major 
roles in many types of cancers including prostate cancer.3-6 Both the genetic deletion or 
pharmacological inhibition of key steps in the TCA cycle and/or OXPHOS can block cancer 
cell growth in vitro and disease progression in vivo.7-10 Further, metabolic signatures of the 
TCA cycle and OXPHOS correlate with cancer progression and unfavorable 
outcomes.9,11-17 Also, 2-18F-fluoropropionic acid and 11C-acetate, new tracers being used 
for positron emission tomography (PET) imaging, are more sensitive detectors of prostate 
cancer than the glycolysis marker 18F-fluorodeoxyglucose.18-21 These data indicate that 
prostate cancers can exhibit unique metabolic profiles. What is not understood is specifically 
how androgen receptor (AR)-signaling, elevated in 100% of metastatic prostate cancers,22 
impacts cellular metabolism and what role this plays in disease progression.
Prostate cancers express the AR and rely on androgens for growth and survival.23 
Consequently, androgen ablation therapies are the standard of care for late-stage disease. 
While patients with advanced prostate cancer initially respond favorably to androgen 
ablation therapy, most experience a relapse of the disease within 1-2 years. Following this 
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castration-resistant relapse, patients have limited treatment options. Although the hormone-
refractory disease is unresponsive to androgen-deprivation, AR-regulated signaling 
pathways remain active and are necessary for cancer progression.23,24 Thus, both AR itself 
and the processes downstream of the receptor remain viable targets for therapeutic 
intervention.
The master metabolic regulator AMP-activated protein kinase (AMPK) governs overall 
cellular homeostasis by modulating the use of sugars, fats and/or proteins as sources of 
cellular fuel. Recent work from our laboratory has demonstrated that androgens increase 
cellular migration and invasion through the direct upregulation of Ca2+/calmodulin-
dependent protein kinase kinase β (CaMKKβ) and subsequent threonine-172 (refers to 
threonine-183/172 of the AMPKα 1/AMPKα2 isoforms, respectively) phosphorylation/
activation of the catalytic subunit of AMPK.25 Later, two more independent groups 
confirmed our CaMKKβ findings in vitro and in multiple clinical cohorts and suggested 
CaMKKβ also promotes glycolytic flux.26,27 Correspondingly, Park et al demonstrated that 
levels of the serine-79 phosphorylated form of acetyl-CoA carboxylase (ACC), a direct 
target of AMPK, are increased in clinical prostate cancer samples.28 Because of the 
importance of androgen signaling in prostate cancer, and the increasing evidence from other 
laboratories as well as our own that suggest AMPK may have an oncogenic role in certain 
cancer contexts,25-31 we wanted to determine whether AR signaling promoted prostate 
cancer cell growth in part through AMPK signaling. Further, given AMPK's role as a central 
regulator of cellular metabolism, we also wanted to determine whether AR-mediated AMPK 
signaling influenced prostate cancer cell biology through additional mechanisms beyond 
those classically attributed to cancer (i.e. glycolysis).
Results
AMPK is required for androgen-mediated prostate cancer cell growth
Our previous work identified a role for CaMKKβ-AMPK signaling in AR-mediated prostate 
cancer cell migration and invasion.25 Subsequent studies confirmed AR's regulation of 
CaMKKβ in prostate cancer and demonstrated its additional importance in regulating 
prostate cancer growth both in vitro and in vivo.26,27 Additionally, Massie et al showed that 
CaMKKβ augmented cell growth in part through increased glucose metabolism, an effect 
they suggested may be mediated through AMPK.27 In that study, the role of AMPK was 
inferred from experiments that used pharmacological AMP mimetics that, while known 
activators of AMPK, cause cellular stress and therefore, may indirectly affect cell growth. 
Because of these and other known pleiotropic effects of various AMPK modulators (ex. 
compound C blocks AR activity25), we wanted to confirm a direct role for AMPK in AR-
mediated prostate cancer cell growth using molecular approaches. To do so, we blocked 
AMPK activity using siRNAs targeting three separate regions of the predominant catalytic 
subunit of AMPK found in the prostate.25 In both LNCaP and VCaP human prostate cancer 
cells, siRNA-mediated knockdown of AMPKα1 decreased the levels of both total AMPKα 
and the threonine-172/activation loop phosphorylated form of AMPKα, indicating blocked 
AMPK activity (Figs. 1A and B). Importantly, all three siRNAs targeting AMPK 
significantly inhibited R1881 (a synthetic androgen)-mediated prostate cancer cell growth in 
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both cell types (Figs. 1C and D), an effect that was observed by three days (Supplemental 
Fig. S1).
Phosphorylated/Activated AMPK correlates with prostate cancer progression in patients
A tissue microarray (TMA) containing benign and primary cancer tissues was examined by 
immunohistochemistry (IHC) to determine if phospho-AMPK (Thr172), the activating 
phosphorylation site, was increased in prostate cancer (Fig. 2). Staining of p-AMPK in the 
TMA was quantified using a multiplicative staining index of intensity (0-3) and extent (0-3) 
of staining, which yields a 10-point staining index (0-9) as described previously.32-34 In 
benign tissues, weak staining (score 3) was observed in luminal cell cytoplasm in some 
tissues, with other tissues showing no staining. Occasional tissues showed moderate staining 
(score 6). In all cases, staining was uniform within each core. Variable cytoplasmic staining 
was seen in the cancer cells in different tissues ranging from no staining to strong staining 
(score 9). Overall, staining was significantly stronger in cancer (Fig. 2A). Occasional weak 
staining was seen in stromal cells in both benign and cancer tissues. Of note, higher p-
AMPK staining was significantly correlated with biochemical (PSA) recurrence following 
radical prostatectomy (non-recurrent 3.2 ± 0.4 (mean ± SEM, n=29) versus recurrent 4.6 ± 
0.4 (n=32))(Fig. 2B). The p-AMPK IHC score was not correlated with pathological 
variables such as Gleason score or disease stage at the time of surgery.
Androgens promote both glycolysis and OXPHOS
Given AMPK's role as a master regulator of metabolism and its regulation by AR in the 
prostate, we next asked what effects androgens had on prostate cancer cell metabolism. To 
quantitate glycolytic rates, we measured the extracellular acidification rate (ECAR) in 
prostate cancer cells following treatment with R1881. In both LNCaP and VCaP cells, 
R1881 increased glycolysis in a dose-dependent manner (Figs. 3A-C). Consistent with what 
has previously been shown,35 the dose response was unaffected by various modulators of 
mitochondrial function (Fig. 3C), highlighting the cytoplasmic nature of glycolysis. 
Interestingly, simultaneous measurement of the oxygen consumption rate (OCR) indicated 
that androgens also increased oxygen consumption in a dose-dependent manner (Figs. 3D-
F). This androgen-mediated increase in OCR was dependent on mitochondrial function as 
combined treatment of rotenone and antimycin, inhibitors of mitochondrial respiration, 
collapsed the response (Fig. 3F). The increased oxygen consumption indicated androgens 
promote metabolism not only through glycolysis, but also through the TCA cycle. In support 
of this, we used MS/MS to show that androgens increased intracellular levels of acetyl-CoA, 
the entry molecule for the TCA cycle (Fig. 3G). Importantly, GC/MS was used to 
demonstrate that androgens also increased the levels of all TCA cycle intermediates tested, 
suggesting that acetyl-CoA is not only entering the TCA cycle, but also metabolized 
completely through it (Fig. 3H). These data are in contrast to Massie et al who found that 
androgen treatment increased citrate but not succinate levels nor oxygen consumption.27 To 
verify whether complete oxidation was occurring, we used a radiolabeled CO2 trap assay to 
demonstrate that androgens increase complete glucose oxidation (Fig. 3I; Supplemental Fig. 
S2A). These results indicate that androgens promote the uptake and metabolism of 
radiolabeled glucose through at least ∼1.5 turns of the TCA cycle prior to the radiolabeled 
1-carbon of glucose being release in the form of CO2.
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While the majority of metabolic cancer research focuses on the role of glucose, recently 
several groups have demonstrated an important role for fatty acid metabolism in prostate 
cancer.18,36-38 Correspondingly, in our hands, β-oxidation was required for maximal 
androgen-mediated prostate cancer cell growth as co-treatment with etomoxir, an inhibitor 
of carnitine palmitoyltransferase I—the rate-limiting step of β-oxidation, suppressed 
androgen-mediated LNCaP growth (Fig. 3J). We therefore tested whether androgens could 
also promote fatty acid oxidation in prostate cancer cells by tracking the metabolism of 
radiolabeled fatty acids. Treatment of either LNCaP (Figs. 3K-L) or VCaP (Supplemental 
Figs. S2B and C) cells with increasing concentrations of androgens promoted, in a dose-
dependent manner, the complete oxidation of both the saturated fatty acid palmitate and the 
monounsaturated fatty acid oleate, two of the most common β-oxidation substrates. 
Importantly, this correlates with previous clinical data demonstrating the increased 
metabolism of both sugars and fats in aggressive metastatic prostate cancers compared to 
localized tumors.39 Taken together, these findings indicate that androgens increase both 
glycolysis (sugars) and OXPHOS (sugars and fats) in prostate cancer cells.
AMPK is required for androgen-mediated OXPHOS
AMPK is a positive regulator of OXPHOS. Given that AMPK is required for androgen-
mediated prostate cancer cell growth (Fig. 1), we next wanted to determine whether the 
androgen-mediated increase in OXPHOS was mediated by AMPK. To do this, we used two 
different approaches. First, we demonstrated in both LNCaP and VCaP cells that molecular 
knockdown of AMPK decreased androgen-mediated oxygen consumption (Figs. 4A and B). 
Second, knockdown of AMPK significantly inhibited the androgen-mediated oxidation of 
radiolabeled glucose (Figs. 4C and D), palmitate (Figs. 4E and F) and oleate (Figs. 4G and 
H).
One of the major functions of mitochondrial OXPHOS is to generate ATP. We therefore 
wanted to determine whether the androgen-mediated OXPHOS indeed led to an increase in 
intracellular ATP levels and hence, helped fulfill the cancer cell's bioenergetic demands. 
Using a luciferase-based ATP assay, we determined that R1881 increased intracellular ATP 
levels in a dose-dependent manner (Fig. 5A). This R1881-mediated increase in ATP levels 
was blocked by transfection with the siRNAs targeting AMPK (Fig. 5B). These results 
indicate that androgens increase mitochondrial function through AMPK.
Androgen-mediated AMPK signaling increases PGC-1α levels, which are elevated in a 
subpopulation of prostate cancers
Our data indicate that androgens increase overall mitochondrial function. However, the 
mechanism for this effect was still unknown. One of the known targets of AMPK is 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a 
transcriptional coactivator that is a master regulator of mitochondrial biogenesis and 
function.40 Therefore, we tested whether androgens could increase PGC-1α levels in 
prostate cancer cells. Androgens, starting at 100 pM, significantly increased PGC-1α protein 
levels in a dose-dependent manner in both LNCaP (Fig. 6A) and VCaP (Fig. 6B) prostate 
cancer cells. Using qPCR, we found that increasing concentrations of R1881 could also 
increase PGC-1α mRNA levels in LNCaP (Fig. 6C) and VCaP (Fig. 6D) cells after a 72 
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hour treatment. This induction was not seen following a 24-hour treatment (Supplemental 
Fig. S3). Interestingly, despite the robust expression of AR, androgens did not significantly 
alter PGC-1α levels in a stepwise genetic model of prostate cancer progression41 
(Supplemental Fig. S4). This is not completely surprising given a) the heterogeneous nature 
of prostate cancer and b) in culture, none of these cells display an androgen-mediated 
growth response.41 However, using a hormone-inducible rat model of benign prostatic 
hyperplasia (BPH), we observed that while testosterone treatment increased prostate 
growth,42,43 it did not increase PGC-1α protein levels (Supplemental Fig. S5). This is in 
contrast to the increased PGC-1α levels observed in tumors derived from the dorsolateral 
lobes of the well-characterized Pb-Cre, Ptenf/f mouse model of prostate cancer44 
(Supplemental Fig. S6) or the Pb-Myc mouse model of prostate cancer45. Additionally, 
comparison of parental LNCaP cells to their castration-resistant prostate cancer (CRPC)-
derivative C4-2 cell line (derived from castration-resistant selection in xenografts) 
demonstrates that p-AMPK and, accordingly, PGC-1α levels are markedly elevated in the 
CRPC C4-2 model relative to parental LNCaPs (Fig. 6E). Xenograft-derived LAPC9 tumors 
that were either propagated in intact mice or serially propagated for 13 generations in 
castrated mice revealed that, despite decreased AR levels, PGC-1α levels are maintained 
and surprisingly, total AMPK and, subsequently, p-AMPK levels are increased in the CRPC 
model (Fig. 6E). While this is the first time we had observed changes in total AMPK levels, 
it is important to note that AMPKα1/PRKAA1 (the predominant isoform of the catalytic 
subunit of AMPK expressed in the prostate25) levels correlate with poor prognosis in 
patients (Supplemental Fig. S7).22 These findings corroborate the clinical p-AMPK TMA 
data shown in Figure 2. Taken together, our results suggest that AMPK-PGC-1α signaling 
correlates with cancer growth and can be indirectly regulated by AR.
To test whether AMPK was responsible for the androgen-mediated increase in PGC-1α 
levels, we used the same siRNAs targeting AMPK described in Figure 1 to determine what 
effects they had on both basal and androgen-mediated PGC-1α levels (Figs. 6F and G; 
Supplemental Fig. S8). In LNCaP and VCaP cells, knockdown of AMPK led to a significant 
decrease in both PGC-1α protein (Fig. 6F; Supplemental Figs. S8A and B) and mRNA (Fig. 
6G; Supplemental Fig. S8C) levels, demonstrating a clear requirement for AMPK in AR-
mediated induction of PGC-1α. Finally, stable knockdown of PGC-1α suppressed prostate 
cancer cell growth/survival over three days roughly 40% in LNCaP cells (Supplemental Fig. 
S8D) and, importantly, 50% in the CRPC C4-2 model (Fig. 6H), highlighting a potential 
role for PGC-1α in the advanced disease.
Given that PGC-1α levels were increased in multiple models of prostate cancer, we next 
determined if its expression correlated with prostate cancer in patients. Analysis of clinically 
annotated prostate cancer data sets accessible through Oncomine revealed that PGC-1α 
expression was significantly higher in cancers compared to controls (Supplemental Fig. 
S9A).46 While this increase was significant, it was derived from a study with a modest 
cohort size (19 patients). Because of the high degree of heterogeneity in prostate cancer, we 
asked whether PGC-1α levels might be elevated in a subset of cancers. Using outlier 
analysis, we found that PGC-1α was indeed overexpressed in a subpopulation of prostate 
cancers in multiple clinical cohorts (Supplemental Fig. S9B).46-50 To better clinically define 
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this subset of patients, we took advantage of the emerging well-annotated datasets available 
from The Cancer Genome Atlas. Here, PGC-1α is significantly overexpressed in ∼5% of 
prostate cancer patients (no patients had significantly decreased expression). These patients 
exhibited clinical pathologic T stages from T2c-T3b and Gleason scores from 7-9 with a 
mean of 7.4. Interestingly, patients from this subpopulation are initially diagnosed with 
prostate cancer significantly earlier (56.0 ± 1.5 years old versus 60.2 ± 0.5 years for the 
average prostate cancer patient).
AR-AMPK-PGC-1α signaling promotes mitochondrial biogenesis and cell growth
Mitochondrial function is essential for both basic cellular homeostasis as well as increased 
cell growth.51 Given recent studies that suggest a previously underappreciated role for 
mitochondrial function in cancer,3-17 we decided to test whether androgens could increase 
mitochondrial biogenesis in prostate cancer cells. Using transmission electron microscopy 
(TEM), we found that LNCaP cells treated for 72 hours had significantly more mitochondria 
(Fig. 7A). To test whether the AMPK-mediated induction of PGC-1α promoted androgen-
mediated mitochondrial biogenesis in a more unbiased manner, we used confocal 
microscopy and subsequent image analysis to quantitatively assess if AMPK and/or PGC-1α 
were required (Figs 7B-D; Supplemental Figs. S10 and 11). Using our two most efficacious 
siRNAs targeting AMPK25 or PGC-1α (Supplemental Fig. S11), siRNA-mediated 
knockdown of either AMPK or PGC-1α significantly decreased mitochondrial volume in 
LNCaP and VCaP cells (Figs. 7B-D; Supplemental Figs. S10 and 11). Similar to knockdown 
of AMPK (Figs. 1 and 4), molecular inhibition of PGC-1α also blocked androgen-mediated 
OXPHOS (Fig. 7E) and, in concordance with what others have reported,52 prostate cancer 
cell growth (Fig. 7F), an effect that was observed by three days (Supplemental Figs. S11C 
and D). However, it should be noted that unlike what has previously been reported,52 in our 
hands PGC-1α did not feedback to further potentiate AR activity (Supplemental Fig. S12). 
Collectively, these results indicate a role for a more linear AR-AMPK-PGC-1α signaling 
cascade in prostate cancer cell growth.
Discussion
While much of the research on cancer metabolism has historically focused on glycolysis, it 
is now becoming apparent that not all cancers depend solely on glycolytic metabolism. 
Prostate cancer, in particular, appears to utilize other processes to fulfill its metabolic 
demands. Accordingly, the glycolysis marker 18F-fluorodeoxyglucose is a relatively poor 
PET imaging marker for prostate cancer.18,19 Conversely, labeled fatty acid and acetate 
analogs, which can be shuttled to fatty acid metabolism and/or enter the TCA cycle, have 
shown more promising results.18,20,21 Interestingly, zinc and citrate levels are higher in 
normal prostate epithelial cells than any other cell in the body. When prostate epithelial cells 
become cancerous, they are uniquely characterized by decreased zinc and citrate levels, 
which parallels with increased citrate oxidation and OXPHOS.5,6 Further, mitochondrial 
biogenesis, TCA cycle and OXPHOS signatures correlate with unfavorable outcomes in 
prostate cancer as well as other cancer types.3,11,13,15,16,53-56 Inhibition of mitochondrial 
function/OXPHOS results in cell death or cell cycle arrest in multiple cancer types.8-10,17 
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Thus, while glycolysis is a major metabolic pathway in cancer, mitochondrion-mediated 
functions still appear essential for many cancer cell types including prostate.
The findings above suggest that mitochondria could be an important target for various 
oncogenic and tumor suppressor signaling cascades. Correspondingly, the telomerase 
oncogene promotes mitochondrial biogenesis and prostate cancer bone metastasis while the 
tumor suppressor p53 suppresses PGC-1-mediated mitochondrial biogenesis.13,54,55 Our 
data presented here indicate that AR signaling also increases AMPK-PGC-1-mediated 
mitochondrial biogenesis and prostate cancer cell growth (Fig. 7). This raises the question of 
how mitochondrial biogenesis contributes to cell growth. One obvious possibility is that 
rapidly dividing cells have high bioenergetic demands. By increasing the mitochondrial 
content of the cell, androgens also increased the intracellular levels of ATP (Fig. 5). 
Recently, however, it has been determined that the level of building blocks (ex. amino acids 
for protein production, etc), rather than the level of ATP, may be the major rate-limiting 
factor for rapidly dividing cells.4 As such, making sure a high level of TCA cycle 
intermediates are maintained, a process termed anaplerosis, would be essential as the TCA 
cycle serves as a central metabolic hub from which many of the cellular building blocks are 
derived (Fig. 8). Our findings that androgens increase TCA cycle intermediate levels and 
promote the metabolism of glucose and fatty acids through the TCA cycle (Fig. 3), suggest 
that AR signaling is also anaplerotic. Current studies are ongoing to determine where 
substrates are ultimately shuttled following androgen treatment.
The data presented here indicate that AMPK signaling is required for androgen-mediated 
prostate cancer cell growth and is elevated in prostate cancer and, importantly, recurrent 
prostate cancer (Figs. 1 and 2). To date, the role of AMPK in cancer has been enigmatic. We 
(data not shown), and others,57 have demonstrated that 5-aminoimidazole-4-carboxamide 1-
β-D-ribo-furanoside (AICAR) and the antidiabetic drugs metformin and rosiglitazone, which 
all activate AMPK, also inhibit prostate cancer cell growth. Conversely, while Massie et al 
also found that metformin inhibited LNCaP cell growth, they showed AICAR increased 
LNCaP cell growth in the presence or absence of androgens. Additionally, AICAR was able 
to rescue the growth inhibitory effects of either CaMKKβ RNAi knockdown or STO-609 
(CaMKK antagonist) treatment.27 Further, AMPK has been shown to be activated in clinical 
prostate cancer samples and inhibition of its activity by compound C or siRNAs targeting 
AMPK blocks cancer cell growth (Figs. 1 and 2).28 These discrepancies may be due to the 
pleiotropic effects of the various small molecules being used to modulate AMPK activity. 
For example, AICAR functions by inducing cellular stress. One of the results of this 
increased cellular stress is the activation of AMPK. However, the widespread increase in 
cellular stress may undoubtedly function to inhibit cellular growth through other stress 
signaling pathways. Alternatively, the pro-growth effects of AMPK may, similar to many 
signaling cascades, occur within a defined window of activity where some controlled AMPK 
activity promotes a metabolic shift that enhances cell growth but too much AMPK activity 
signals stress and subsequent cell cycle arrest.
In prostate cancer cells, androgens increase PGC-1α protein and mRNA levels (Figs. 6A-D). 
While we know AMPK is required for this PGC-1α regulation (Figs. 6F and G; 
Supplementary Fig. S8), we still do not understand the exact mechanism. Previously, Bruce 
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Spiegelman's laboratory demonstrated that AMPK increases both PGC-1α protein and 
mRNA levels in skeletal muscle.40 In that study, they found that AMPK directly 
phosphorylates PGC-1α on threonine-177 and serine-538. These phosphorylation events 
then increase the activity of PGC-1α protein on its own promoter, increasing its expression 
through a mechanism that may involve the transcription factors GATA-4 and Upstream 
Stimulatory Factor-1.58 Hence, the AR-AMPK mediated increase in PGC-1α protein and 
mRNA levels may occur through the direct posttranslational phosphorylation of PGC-1α 
protein by AMPK and subsequent positive feedback expression of the PPARGC1A gene.
Our data correlate with recent findings that indicate PGC-1α signaling is upregulated in 
endometrial cancer,12 drives breast cancer tumor growth in vivo,59 and Pgc1α-/- mice are 
resistant to chemically-induced models of colon and liver cancer.7 Correspondingly, Shiota 
et al also demonstrated that PGC-1α was essential for prostate cancer cell growth.52 
Interestingly, in that study, PGC-1α was shown to function as a coactivator of AR. In our 
hands, we did not observe this effect (Supplemental Fig. S12). Thus, our current data 
indicate AR, via AMPK, increases PGC-1α levels in a more linear manner (Fig. 8). Whether 
AMPK and PGC-1α promote cancer cell growth through additional mechanisms remains to 
be determined. Hence, while AMPK-PGC-1α signaling promotes prostate cancer cell 
growth in part through increasing mitochondrial function (known because inhibition of 
mitochondrial function decreases cell growth/survival (Fig. 3J)10), AMPK-PGC-1α 
signaling may also enhance prostate cancer cell growth through additional, mitochondrion-
independent mechanisms (ex. increasing cyclin D levels, etc). This could also help explain 
why knockdown of PGC-1α had a more dramatic effect on cell growth (Fig. 7F; 
Supplemental Figs. S11C and D) than it did on mitochondrial biogenesis (Figs. 7B-D; 
Supplemental Figs. S10 and 11). The more modest effects on mitochondrial biogenesis were 
likely due to the suboptimal efficacy of our PGC-1α -targeting siRNAs (Supplemental Fig. 
S11). Conversely, the dramatic effect of molecular PGC-1α inhibition on growth suggests 
that PGC-1α may potentiate androgen-mediated prostate cancer cell growth through 
additional mechanisms. As a result, the modest inhibition of a single protein, PGC-1α, 
would result in pronounced overall growth effects.
Collectively, the data presented here suggest that AR signaling promotes AMPK-PGC-1α -
mediated mitochondrial biogenesis and cell growth. This is important because while AR's 
role in prostate cancer has been well established, the mechanisms by which AR manifests its 
biological actions and how these are dysregulated during disease progression are poorly 
understood. As a result, it is essential to identify the AR signaling networks that truly drive 
disease progression. Our understanding of these signaling pathways will ultimately yield 
new therapeutic targets. Hence, as our data indicate, modulators of mitochondrial function 
may offer new therapeutic avenues for AR-driven prostate cancer.
Materials and Methods
Reagents and standard biochemical and molecular approaches
More detailed descriptions of reagents, cell culture, siRNA transfections, Western blot 
analyses, proliferation assays, radiolabeled CO2 trap assays, ATP assays, real-time PCR 
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analyses, microscopy, viability assays and reporter gene assays are provided in the 
Supplementary Information.
Human tissues and tissue microarray analysis
Prostate cancer TMAs were constructed using tissues collected after radical prostatectomy 
with informed consent by the Baylor College of Medicine Human Tissue Acquisition and 
Pathology Core under an IRB-approved protocol. The arrays were 1 mm cores of 80 cancers 
and matched benign tissues with equal numbers of cases with and without biochemical 
recurrence. Arrays stained with anti-phospho-AMPK antibody were carried out as described 
in the Supplementary Material and quantitated using a multiplicative staining index of 
intensity (0-3) and extent (0-3) of staining yielding a 10-point staining index (0-9) as 
described in previous publications.32-34 Some cancer cores could not be scored due to 
exhaustion of tumor in the core and likewise in some cores no benign epithelium was 
present. Overall 61 cancers and 65 benign tissues could be scored. Scoring was performed 
without knowledge of the corresponding clinical and pathological variables.
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurements
ECAR, reflective of the rate of glycolysis, and OCR, reflective of the rate of OXPHOS, 
were measured using a Seahorse Bioscience XF24 analyzer (North Billerica, MA, USA). 
Cells were plated at 30,000 cells/well in Seahorse XF24 plates coated with BD Cell-Tak 
(BD Biosciences) and incubated for 48 hours. For R1881 dose response experiments, the 
cells were then treated for 72 hours. For knockdown experiments, cells were transfected 
with indicated siRNAs overnight prior to treatment. For ECAR and OCR measurements in 
the presence of inhibitors (oligomycin-1.3 μM; Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP)-1 μM; rotenone-1 μM; antimycin A-1 μM), the 
samples were treated with R1881 and then incubated for 72 hours. During the initial/basal 
phase of assaying no inhibitors were present. Thereafter at respective time points inhibitor-
containing media were sequentially injected to the assay wells through automated instrument 
ports. Data were normalized to cell numbers using the DNA content assay described in the 
Supplementary Information.
Metabolic profiling
Measurements of intracellular acetylcarnitine levels, which are reflective of acetyl-CoA 
levels, and organic acid/TCA cycle intermediates were performed using tandem mass 
spectrometry (MS/MS) or gas chromatography/mass spectrometry (GC/MS) as previously 
described.60
Animal studies
ARR2PB-Cre (Pb-Cre) transgenic mice61 were from Dr. Fen Wang (Texas A&M Health 
Science Center, Houston, TX, USA). Ptenf/f mice44 were from Dr. Hong Wu (University of 
California Los Angeles, CA, USA). Breeding, crosses, dissociation of prostate tumors and 
RNA isolation were performed using previously described approaches.62
Adult male Wistar rats (Charles River Laboratories, Wilmington, MA, USA) between 10 
and 11 weeks of age were used as a testosterone-induced model of BPH as previously 
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described. Housing conditions, treatments and isolation of ventral prostates were previously 
described.42,43 All animals remained healthy throughout the experiments. Animal care was 
in accordance with institutional guidelines and complied with NIH policy.
Statistical analysis
Two-sample comparisons were performed using Student's t-tests. Multiple comparisons 
were performed using a one-way ANOVA and post-hoc Dunnett's test with GraphPad 
Prism, Version 4 (GraphPad Software, La Jolla, CA, USA). TMA staining intensity groups 
were compared using Mann-Whitney tests. Kaplan-Meier curves were compared using a 
log-rank test. Significant changes were determined at the P < 0.05 level unless otherwise 
noted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
AMPK is required for androgen-mediated prostate cancer cell growth. A and B, LNCaP (A) 
or VCaP (B) cells were transfected with mock or siRNAs targeting a β-lactamase negative 
control (siControl) or AMPKα1 (#1-3). The following day, cells were treated for 72 hours ± 
10 nM R1881 (synthetic androgen). Whole cell extracts were subjected to Western blot 
analysis using GAPDH as a loading control. C and D, LNCaP (C) and VCaP (D) cells were 
transfected the same as in A and B and then treated for 7 days ± R1881. Cells were then 
lysed and the relative number of cells was quantified using a fluorescent DNA-binding dye. 
Results are expressed as mean relative cell number + SE (n = 3). *, significant changes from 
vehicle-treated cells.
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Figure 2. 
Phosphorylated/Activated AMPK correlates with clinical prostate cancer progression. A, 
examples of IHC with anti-phospho-AMPK antibody (Thr172). The staining index for 
benign and cancer epithelial cells is indicated under each figure. Original magnification: 
100X. Box plot of staining index of prostate cancer (n = 61) and benign tissues (n = 65) is 
also shown. The difference in staining index was highly statistically significant (p < .001, 
Mann-Whitney). B, comparison of staining index of non-recurrent (n = 29) and recurrent (n 
= 32) tumors following radical prostatectomy. Staining was significantly higher in the 
recurrent group (p = .017, Mann-Whitney).
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Figure 3. 
Androgens promote glycolysis and OXPHOS in prostate cancer cells. A and B, LNCaP (A) 
or VCaP (B) cells were treated for 72 hours with increasing concentrations of R1881 (0, 
0.01, 0.1, 1, and 10 nM). Extracellular acidification rates (ECARs) were then measured 
using a Seahorse XF Analyzer and values were normalized to cell numbers. Results are 
expressed as ECAR normalized to cell numbers + SE (n = 3). C, LNCaP cells were treated 
and analyzed for ECAR as in A but were also tested for effects on ECAR in the sequential 
presence of oligomycin, FCCP and a combination of rotenone and antimycin A. D and E, 
LNCaP (D) and VCaP (E) cells were treated the same as in A and B. At the same time 
ECAR rates were being measured, simultaneous oxygen consumption rates (OCRs) were 
measured and normalized the same as in A and B. F, LNCaP cells were treated and analyzed 
for OCR as in D but were also tested for effects on OCR in the sequential presence of 
oligomycin, FCCP and a combination of rotenone and antimycin A. G, LNCaP cells were 
treated for 72 hours with increasing doses of R1881 (0, 0.1, 1, and 10 nM). Acetyl-CoA 
levels were then measured using MS/MS and normalized to total protein. Results are 
expressed as acetyl-CoA levels normalized to total protein + SE (n = 3). H, LNCaP cells 
were treated as in G. TCA cycle intermediate levels were then measured using GC/MS and 
normalized to total protein. Results are expressed as metabolite levels normalized to total 
protein + SE (n = 2). I, LNCaP cells were treated as in A and then incubated with 14C-
labeled glucose and subjected to a CO2 trap assay to measure complete glucose oxidation 
and normalized to cell numbers. Results are expressed as fold counts per minute (CPM) 
normalized to cell numbers + SE (n = 3). J, LNCaP cells were cotreated for 7 days with 
increasing doses of R1881 in the presence of vehicle (DMSO) or the β-oxidation inhibitor 
etomoxir (100 μM). Relative cell numbers were then determined as in Fig. 1. K and L, 
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LNCaP cells were treated and subjected to a CO2 trap assay the same as in I, but using 14C-
labeled palmitate (K) or oleate (L) to quantitate the levels of fatty acid oxidation. *, 
significant changes from vehicle-treated cells.
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Figure 4. 
Androgen-mediated OXPHOS requires AMPK. A and B, LNCaP (A) or VCaP (B) cells 
were transfected and treated as in Figs. 1A and B. OCRs were then measured using the 
Seahorse Analyzer and normalized to cell numbers as described in Fig. 3. C and D, LNCaP 
(C, E, G) or VCaP (D, F, H) cells were transfected and treated as described in A and B. 
Oxidation of radiolabeled glucose (C and D), palmitate (E and F) and oleate (G and H) were 
then measured using CO2 trap assays and normalized to cell numbers as in Fig. 3. *, 
significant changes from vehicle-treated cells.
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Figure 5. 
Androgens increase intracellular ATP levels through AMPK. A, LNCaP cells were treated 
the same as in Fig. 3G. ATP levels were then quantitated using a luciferase-based assay and 
data were normalized to cell numbers. Results are expressed as relative ATP levels 
normalized to cell numbers + SE (n = 3). B, cells were transfected and treated as in Fig. 1A. 
ATP levels were then quantitated and normalized as in A. *, significant changes from 
vehicle-treated cells.
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Figure 6. 
AR-AMPK signaling increases PGC-1α levels. A-D, prostate cancer cells were treated with 
increasing concentrations of R1881 for 72 hours. A left, representative LNCaP Western 
blots following treatment (0, 0.1, 1 and 10 nM R1881). A right, LNCaP immunoblot 
densitometry values. PGC-1α levels were normalized to GAPDH (n = 4). B left, 
representative VCaP Western blots following treatment (0, 0.01, 0.1, 1 and 10 nM R1881). 
B right, VCaP immunoblot densitometry values. PGC-1α levels were normalized to 
GAPDH (n = 4). C and D, LNCaP (C) and VCaP (D) cells treated for 72 hours with 0, 0.01, 
0.1, 1 or 10 nM R1881. After treatment, cells were lysed and RNA was isolated and reverse 
transcribed. The expression of PGC-1α was assessed using qPCR (n = 3). E, cell/tumor 
lysates from untreated parental LNCaP and CRPC-derivative C4-2 cells or LAPC9-derived 
androgen-dependent (LAPC9-AD) and CRPC (LAPC9-AI) tumor xenografts were subjected 
to Western blot analysis. F and G, LNCaP cells were transfected and treated as described in 
Fig. 1A. Cells were then subjected to immunoblot (F) or qPCR (G) analysis (n = 3). 
Densitometry values for F are presented in Supplementary Fig. S8B. *, significant changes 
from vehicle-treated cells. H, C4-2 cells stably expressing shRNAs targeting either scramble 
control (shControl) or PGC-1α (shPGC-1α) were subjected to a 3-day cell growth/viability 
assay. Inset, Western blot control demonstrating PGC-1α stable knockdown. *, significant 
change from shControl cells.
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Figure 7. 
AR-AMPK signaling increases PGC-1α -mediated mitochondrial biogenesis, OXPHOS and 
cell growth. A, LNCaP cells were treated ± 10 nM R1881 for 72 hours and then subjected to 
TEM analysis. Shown are representative images (left) and results from blinded scoring of 
mitochondrial numbers/section (right). B-D, VCaP (Figs. 7B and C) and LNCaP (Fig. 7D 
and Supplementary Fig. S10) cells were transfected with indicated siRNAs and treated as in 
Figs. 1A and B. Mitochondrial volume was then assessed using fluorescence confocal 
microscopy and subsequent image analysis. Shown are representative images (Fig. 7B and 
Supplementary Fig. S10) and quantitated morphometric analysis (Figs. 7C and D). Scale 
bar, 10 μm. E, LNCaP cells were transfected with indicated siRNAs and treated as described 
in D. Oxidation of radiolabeled glucose was then measured using a CO2 trap assay and 
normalized to cell numbers as in Fig. 4. *, significant changes from vehicle-treated cells. F, 
LNCaP cells were transfected as in E and then treated for 7 days ± R1881. Relative cell 
numbers were determined using the assay described in Fig. 1. *, significant changes from 
vehicle-treated cells.
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Figure 8. 
Proposed model of the AR-AMPK-PGC-1α signaling axis. Androgens, through AR, 
increase AMPK activity. AMPK then potentiates PGC-1α. Increased PGC-1α can then 
promote mitochondria biogenesis and function.
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